ERIVANCE BCC: efficacy and safety of vismodegib in advanced basal cell carcinoma
The hedgehog pathway inhibitor vismodegib shrank tumours in 43 percent of patients with locally advanced and 30 percent with metastatic basal cell carcinoma, becoming the first drug approved for advanced basal cell carcinoma.
Overview
Phase 2 study of 104 patients with metastatic (33) or locally advanced (71) basal cell carcinoma unsuitable for surgery or radiotherapy treated with vismodegib 150 mg daily.
Objective response was 30 percent in metastatic and 43 percent in locally advanced disease (21 percent complete), with median duration of response of 7.6 months; muscle spasms, alopecia, dysgeusia and weight loss were almost universal and led many patients to stop.
- Objective response 43 percent (locally advanced) and 30 percent (metastatic).
- Median duration of response 7.6 months.
Vismodegib (and sonidegib) is the first-line systemic treatment for locally advanced or metastatic basal cell carcinoma, often given intermittently to manage side effects.
- Single-arm; toxicity-related discontinuation is common.
- Teratogenic; strict contraception required.
Similar pages
not linked directly; found by shared links- TrialTo Assess the Safety and Efficacy of SP-002 with Vismodegib for the Treatment of Locally Advanced Basal Cell Carcinoma
Shares Vismodegib, Locally advanced and metastatic basal cell carcinoma.
- TechnologyHedgehog pathway inhibitors
Shares ERIVANCE BCC, Vismodegib, Locally advanced and metastatic basal cell carcinoma.
- PathwayBasal cell carcinoma (KEGG map)
Shares ERIVANCE BCC, Vismodegib, Locally advanced and metastatic basal cell carcinoma.
- TreatmentPatidegib
Shares Vismodegib, Locally advanced and metastatic basal cell carcinoma.
- TargetSmoothened (hedgehog pathway)
Shares ERIVANCE BCC, Vismodegib, Locally advanced and metastatic basal cell carcinoma.
- PathwayHedgehog signalling
Shares ERIVANCE BCC, Locally advanced and metastatic basal cell carcinoma.
- CancerBasal cell carcinoma
Shares ERIVANCE BCC, Vismodegib, Locally advanced and metastatic basal cell carcinoma.